Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
7
AXIM Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
0.95%
Day range:
$0.0016 - $0.0019
52-week range:
$0.0013 - $0.0206
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.14x
P/B ratio:
--
Volume:
891.4K
Avg. volume:
1.1M
1-year change:
-90.91%
Market cap:
$545.2K
Revenue:
$39.5K
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies
|
-- | -- | -- | -- | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies
|
$0.0018 | -- | $545.2K | -- | $0.00 | 0% | 6.14x |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.36 | -- | $4.3M | -- | $0.00 | 0% | 1.40x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.14 | $100.00 | $3.2M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies
|
-224.48% | -6.615 | 226.27% | 0.00x |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies
|
$15.7K | -$569.4K | -- | -- | -11619.41% | $553K |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
AXIM Biotechnologies vs. Competitors
-
Which has Higher Returns AXIM or IBIO?
iBio has a net margin of -12985.96% compared to AXIM Biotechnologies's net margin of -4444.57%. AXIM Biotechnologies's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies90.02% -$0.01 -$2.9M IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About AXIM or IBIO?
AXIM Biotechnologies has a consensus price target of --, signalling downside risk potential of --. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that iBio has higher upside potential than AXIM Biotechnologies, analysts believe iBio is more attractive than AXIM Biotechnologies.
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies0 0 0 IBIOiBio0 0 0 -
Is AXIM or IBIO More Risky?
AXIM Biotechnologies has a beta of 0.987, which suggesting that the stock is 1.315% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock AXIM or IBIO?
AXIM Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or IBIO?
AXIM Biotechnologies quarterly revenues are $17.5K, which are smaller than iBio quarterly revenues of $175K. AXIM Biotechnologies's net income of -$2.3M is higher than iBio's net income of -$4M. Notably, AXIM Biotechnologies's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies is 6.14x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies6.14x -- $17.5K -$2.3M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns AXIM or NBY?
NovaBay Pharmaceuticals has a net margin of -12985.96% compared to AXIM Biotechnologies's net margin of -49.65%. AXIM Biotechnologies's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies90.02% -$0.01 -$2.9M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About AXIM or NBY?
AXIM Biotechnologies has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than AXIM Biotechnologies, analysts believe NovaBay Pharmaceuticals is more attractive than AXIM Biotechnologies.
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is AXIM or NBY More Risky?
AXIM Biotechnologies has a beta of 0.987, which suggesting that the stock is 1.315% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock AXIM or NBY?
AXIM Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or NBY?
AXIM Biotechnologies quarterly revenues are $17.5K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. AXIM Biotechnologies's net income of -$2.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, AXIM Biotechnologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies is 6.14x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies6.14x -- $17.5K -$2.3M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns AXIM or OGEN?
Oragenics has a net margin of -12985.96% compared to AXIM Biotechnologies's net margin of --. AXIM Biotechnologies's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies90.02% -$0.01 -$2.9M OGENOragenics-- -$0.38 -- -
What do Analysts Say About AXIM or OGEN?
AXIM Biotechnologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 25237.83%. Given that Oragenics has higher upside potential than AXIM Biotechnologies, analysts believe Oragenics is more attractive than AXIM Biotechnologies.
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies0 0 0 OGENOragenics0 0 0 -
Is AXIM or OGEN More Risky?
AXIM Biotechnologies has a beta of 0.987, which suggesting that the stock is 1.315% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock AXIM or OGEN?
AXIM Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or OGEN?
AXIM Biotechnologies quarterly revenues are $17.5K, which are larger than Oragenics quarterly revenues of --. AXIM Biotechnologies's net income of -$2.3M is higher than Oragenics's net income of -$2.5M. Notably, AXIM Biotechnologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies is 6.14x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies6.14x -- $17.5K -$2.3M OGENOragenics1.40x -- -- -$2.5M
-
Which has Higher Returns AXIM or PTN?
Palatin Technologies has a net margin of -12985.96% compared to AXIM Biotechnologies's net margin of -2357.27%. AXIM Biotechnologies's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies90.02% -$0.01 -$2.9M PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About AXIM or PTN?
AXIM Biotechnologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than AXIM Biotechnologies, analysts believe Palatin Technologies is more attractive than AXIM Biotechnologies.
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies0 0 0 PTNPalatin Technologies0 0 0 -
Is AXIM or PTN More Risky?
AXIM Biotechnologies has a beta of 0.987, which suggesting that the stock is 1.315% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock AXIM or PTN?
AXIM Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or PTN?
AXIM Biotechnologies quarterly revenues are $17.5K, which are smaller than Palatin Technologies quarterly revenues of $350K. AXIM Biotechnologies's net income of -$2.3M is higher than Palatin Technologies's net income of -$7.8M. Notably, AXIM Biotechnologies's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies is 6.14x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies6.14x -- $17.5K -$2.3M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns AXIM or TOVX?
Theriva Biologics has a net margin of -12985.96% compared to AXIM Biotechnologies's net margin of --. AXIM Biotechnologies's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies90.02% -$0.01 -$2.9M TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About AXIM or TOVX?
AXIM Biotechnologies has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than AXIM Biotechnologies, analysts believe Theriva Biologics is more attractive than AXIM Biotechnologies.
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies0 0 0 TOVXTheriva Biologics1 0 0 -
Is AXIM or TOVX More Risky?
AXIM Biotechnologies has a beta of 0.987, which suggesting that the stock is 1.315% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock AXIM or TOVX?
AXIM Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or TOVX?
AXIM Biotechnologies quarterly revenues are $17.5K, which are larger than Theriva Biologics quarterly revenues of --. AXIM Biotechnologies's net income of -$2.3M is higher than Theriva Biologics's net income of -$7.7M. Notably, AXIM Biotechnologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies is 6.14x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies6.14x -- $17.5K -$2.3M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
